Search Results for “HIV” – Page 8 – media

Hengrui Medicine plans to be listed on the Hong Kong Stock Exchange?

According to overseas media Bloomberg, Jiangsu Hengrui Medicine Co., Ltd. is considering a second listing in Hong Kong next year. People familiar with the matter said that the company is discussing potential share sales with consultants, which may raise at least US$2 billion (about HK$15.5 billion). This news has attracted widespread attention. In response, Hengrui Medicine said that it “would not comment” on the rumor.Affected by this news, Hengrui Medicine’s stock price has fluctuated significantly, and its current market value is about RMB 300 billion (US$43 billion). In recent years, “A+H” stocks have continued to expand. With the listing of Midea Group on the Hong Kong Stock Exchange on September 17, there are currently 150 companies that have successfully achieved “A+H” dual listings. Among them are many biopharmaceutical companies, including innovative pharmaceutical companies: Innovent Biologics, Fudan Zhangjiang, CanSino Biologics, Rongchang Bio, Junshi Biosciences, BeiGene, etc., traditional pharmaceutical companies: Shanghai Pharmaceuticals, ...
- Source: drugdu
- 62
- October 31, 2024
Huiyu Pharmaceuticals was the first company to pass the review for its “Detoxification Injection”

From October 14 to October 20, a total of 59 varieties passed/are deemed to have passed the consistency evaluation. During the same period, 88 varieties applied for consistency evaluation. Huiyu Pharmaceutical: Acetylcysteine Injection According to the official website of NMPA, Huiyu Pharmaceutical’s acetylcysteine injection was approved for marketing on October 16. The specifications approved this time are: 30ml: 6g, and the indications are detoxification of acute acetaminophen poisoning, used to prevent or alleviate liver damage caused by its overdose. Acetylcysteine is a precursor of reduced glutathione (GSH) and is an oxygen free radical scavenger in the body. The mechanism of its liver protection is still unclear, and may be related to maintaining or restoring glutathione levels. In addition, acetylcysteine may also play a liver protection role by improving hemodynamics and oxygen transport capacity and expanding microcirculation. As of now, Huiyu Pharmaceutical’s acetylcysteine injection is the first and only product of ...
- Source: drugdu
- 61
- October 31, 2024
Medtronic’s’ 2 Medical Devices’ Approved for Market by FDA

Recently, Medtronic announced that its Affera radiofrequency ablation system and Sphere-9 catheter have been approved for market by the US Food and Drug Administration (FDA). It is understood that this is an integrated electrophysiological product capable of pulsed field ablation (PFA) and radiofrequency (RF) ablation, approved for the treatment of persistent atrial fibrillation (AFib) and tricuspid isthmus dependent atrial flutter, and previously obtained CE marking approval in March 2023. Innovative products demonstrate differentiation advantages The two medical devices approved this time originated from Affera, which Medtronic acquired for $1 billion in August 2022 and introduced these technologies. The competition in the field of electrophysiology is fierce, and Medtronic has further solidified its position with these two medical devices. The Affera radiofrequency ablation system is an integrated high-resolution mapping and treatment solution that provides more predictable and flexible surgery, allowing doctors to accurately map and ablate using radiofrequency and electrical pulse ...
- Source: drugdu
- 73
- October 30, 2024
Endoscopic equipment company completes over 100 million yuan Series B financing

Recently, Shenzhen Xingchen Sea Medical Technology Co., Ltd. (hereinafter referred to as “Xingchen Sea Medical”) announced the completion of a Series B financing of over 100 million yuan, led by Yuansheng Venture Capital, with continued investment from old shareholders Junlian Capital and Daotong Investment, and Haoyue Capital serving as the exclusive financial advisor. It is reported that this round of financing will help Xingchen Hai Medical further expand its production capacity, accelerate new product research and development, and expand its global market, promoting its rapid development in the field of disposable endoscopes. Complete 4 rounds of financing Xingchen Sea Medical was established in October 2020, with a founding team from domestic and foreign head medical device companies. With over ten years of experience in minimally invasive surgical product research and development, global marketing, and production management, we are committed to becoming an innovative leader in endoscopic intervention diagnosis and treatment. ...
- Source: drugdu
- 66
- October 29, 2024
Sinocell’s “RSV vaccine 1.2 category new drug” approved for clinical trials

According to the official website of CDE, SCTV02 injection, a Class 1.2 new drug for preventive biological use developed by Sinocell Engineering Co., Ltd. (hereinafter referred to as “Sinocell”), has obtained implicit approval for clinical trials. Its indication is to prevent diseases caused by respiratory syncytial virus (RSV) infection. Respiratory syncytial virus (RSV) is an infectious virus belonging to the genus Pneumovirus of the family Paramyxoviridae. It mainly causes lower respiratory tract infections such as bronchiolitis and pneumonia in infants under 6 months old, and upper respiratory tract infections such as rhinitis and colds in older children and adults. According to statistics, almost all children have been infected with respiratory syncytial virus before the age of 2. Due to the large population base in China, the number of children with lower respiratory tract infections caused by RSV infection ranks relatively high in the world. RSV has always been called the ...
- Source: drugdu
- 76
- October 29, 2024
Lixin Pharmaceuticals Completes RMB 300 Million C1 Round of Financing

Recently, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Lixin Pharmaceutical”) announced that it has successfully completed a C1 round of financing of RMB 300 million. This round of financing was led by China Biopharmaceutical, a well-known domestic industry party, and co-invested by Pudong Venture Capital and Zhang Jianghaoheng. Old shareholders Qiming Venture Partners and Shanghai Biomedicine Fund followed suit. Zhong Lun served as the legal advisor for this round of financing. Lixin Pharmaceuticals also mentioned that it has recently launched the C2 round of financing. The funds raised will be mainly used to accelerate the clinical progress of clinical pipelines, especially LM-302 and LM-108, and support the independently developed antibody discovery platform, next-generation ADC technology platform, and bispecific antibody technology platform, and continue to produce innovative pipelines with international competitiveness. About Lixin Pharmaceuticals Lixin Pharmaceuticals is a biopharmaceutical company based in China and facing the world. It ...
- Source: drugdu
- 76
- October 28, 2024
Fosun Pharma’s Global Innovation Journey

From November 5 to 10, 2024, the 7th China International Import Expo (hereinafter referred to as “CIIE”) will be held in Shanghai. This year marks the 30th anniversary of the founding of Fosun Pharma. As a “full-time student” of the 7th CIIE, Fosun Pharma will continue to work with global partners in the Medical Devices and Healthcare Exhibition Area of Hall 7.1 (Booth No.: 7.1B3-02) to demonstrate its strong strength and far-reaching influence in becoming a global leading medical innovation integrator. Wu Yifang, Chairman of Fosun Pharma, said: “Over the past 30 years, Fosun Pharma has always insisted on innovation-driven development, actively embraced globalization, and deepened international cooperation. We are in sync with the development of the pharmaceutical industry and have demonstrated our innovative achievements and global strategic layout through the CIIE, an important platform for open cooperation. We will continue to promote global operations, accelerate the transformation of source ...
- Source: drugdu
- 66
- October 26, 2024
Medical device giant welcomes new head of China region

On October 21st, Omron Health Medical (China) Co., Ltd. (hereinafter referred to as Omron Health Medical) officially announced the appointment of Chen Xixiao as the Managing Director. After taking office, Chen Xiaoxiao will be fully responsible for the business development and strategic planning of Omron’s healthcare business in China, deepening Omron’s strategic layout in China, continuously enhancing the brand’s influence in the Chinese market, and solidly moving towards the beautiful vision of “Going for ZERO Preventive Medicine, Making the World Healthier”. The new helmsman takes office Omron Group was founded in 1933 by Lishi Yizhen and is a globally renowned manufacturer of automation control and electronic equipment, with expertise in sensing and control core technologies. By continuously creating new social demands, Omron Group has over 28000 employees worldwide and a turnover of 818.8 billion yen. The products cover a wide range of fields such as industrial automation control systems, electronic ...
- Source: drugdu
- 68
- October 25, 2024
Everest Medicines Announces Taiwan’s Approval of the World’s First New Drug Application for Nervosa® for the Treatment of IgA Nephropathy

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the research and development, clinical development, manufacturing and commercialization of innovative drugs, announced today that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® (budesonide enteric-coated capsules, NEFECON®) for the treatment of adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) at risk of progression to delay renal function decline by 1, with no baseline proteinuria level restriction. This means that NEFECON®, as the world’s first and only causal treatment for IgA nephropathy fully approved by the U.S. Food and Drug Administration (FDA), has further expanded its coverage, bringing new hope to more Chinese IgA nephropathy patients. The results of the NefIgArd Phase 3 global clinical trial showed that compared with placebo, NefIgArd® not only brought about a lasting decrease in proteinuria and reduced the risk of microscopic hematuria, but more importantly, it showed clinically relevant and statistically significant treatment ...
- Source: drugdu
- 71
- October 25, 2024
Boston Scientific’s’ 2 Medical Devices’ Approved for Market by FDA

On October 21st, according to foreign media Fierce Biotech, the FARAWAVE NAV ablation catheter and Faraview software integrated with Boston Scientific’s navigation function have been approved by the US Food and Drug Administration (FDA). It is reported that the above two products have been officially launched in the United States, forming part of the Boston Scientific Farapulse Pulsed Field Ablation (PFA) system, providing a new visualization solution for cardiac ablation surgery. New features added The FARAWAVE NAV ablation catheter is an upgrade based on the previous generation PFA product FARAPULSE. It looks very similar to the FARAPULSE ablation catheter in appearance, but the new generation product has many new features that were not present in the previous generation product – magnetic navigation function and equipped with a dedicated 3D FARAVIEW module (software). Therefore, this also enables the FARAWAVE NAV ablation catheter to have both ablation and mapping functions:  Ablation ...
- Source: drugdu
- 84
- October 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.